Figure 10.

IndOH-LNC increase the nestin protein immunocontent in C6 glioma cells. C6 glioma cells were treated with 25 μM of IndOH-LNC for 72 hours. (A) Immunostaining for anti-nestin antibody (red) and DAPI (blue). (B) Quantification of nestin protein immunocontent by Western blot analysis.

Notes: Unloaded LNC were considered the vehicle control of IndOH-LNC. The densitometric values obtained from treatments were normalized to their respective controls (control bar) (100%). Immunocytochemistry experiments were performed at least three times. In the Western blot analysis, bars represent the mean ± standard deviation for six independent experiments. significant differences from control and LNC groups: ***P< 0.001, as assessed by one-way analysis of variance followed by the Bonferroni post hoc test.

Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; IndOH-LNC, indomethacin-loaded lipid-core nanocapsules; LNC, lipid-core nanocapsules.